Multivesicular liposomal bupivacaine at the sciatic nerve

Biomaterials

Volumn 35, Issue 15, 2014, Pages 4557-4564

  McAlvin, J Brian ^a,b   Padera, Robert F ^c   Shankarappa, Sahadev A ^d   Reznor, Gally ^a,b   Kwon, Albert H ^a,e   Chiang, Homer H ^a,b   Yang, Jason ^b   Kohane, Daniel S ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d AMRITA SCHOOL OF ARTS AND SCIENCES   (India)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Bupivacaine; DepoFoam; Exparel ; Inflammation; Myotoxicity; Neurotoxicity

Indexed keywords

ANESTHETICS; BIOCOMPATIBILITY; PATHOLOGY;

BUPIVACAINE; DEPOFOAM; INFLAMMATION; MYOTOXICITY; NEUROTOXICITY;

TISSUE;

BUPIVACAINE; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG DISTRIBUTION; DRUG RELEASE; INFLAMMATION; MALE; MOUSE; MYOTOXICITY; NONHUMAN; PRIORITY JOURNAL; SCIATIC NERVE; TOXICITY;

RATTUS;

BUPIVACAINE; DEPOFOAM; EXPAREL™; INFLAMMATION; MYOTOXICITY; NEUROTOXICITY;

ANESTHETICS, LOCAL; ANIMALS; BUPIVACAINE; INJECTIONS; LIPOSOMES; MALE; RATS; RATS, SPRAGUE-DAWLEY; SCIATIC NERVE;

EID: 84896048806     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.02.015     Document Type: Article

References (69)

1. Castillo J., Curley J., Hotz J., Uezono M., Tigner J., Chasin M., et al. Glucocorticoids prolong rat sciatic nerve blockade invivo from bupivacaine microspheres. Anesthesiology 1996, 85:1157-1166.
2. Curley J., Castillo J., Hotz J., Uezono M., Hernandez S., Lim J.O., et al. Prolonged regional nerve blockade. Injectable biodegradable bupivacaine/polyester microspheres. Anesthesiology 1996, 84:1401-1410.
3. Wakiyama N., Juni K., Nakano M. Preparation and evaluation invitro and invivo of polylactic acid microspheres containing dibucaine. Chem Pharm Bull (Tokyo) 1982, 30:3719-3727.
4. Padera R., Bellas E., Tse J.Y., Hao D., Kohane D.S. Local myotoxicity from sustained release of bupivacaine from microparticles. Anesthesiology 2008, 108:921-928.
5. Drager C., Benziger D., Gao F., Berde C.B. Prolonged intercostal nerve blockade in sheep using controlled-release of bupivacaine and dexamethasone from polymer microspheres. Anesthesiology 1998, 89:969-979.
6. McAlvin J.B., Reznor G., Shankarappa S.A., Stefanescu C.F., Kohane D.S. Local toxicity from local anesthetic polymeric microparticles. Anesth Analg 2013, 116:794-803.
7. Masters D.B., Berde C.B., Dutta S.K., Griggs C.T., Hu D., Kupsky W., et al. Prolonged regional nerve blockade by controlled release of local anesthetic from a biodegradable polymer matrix. Anesthesiology 1993, 79:340-346.
8. Boedeker B.H., Lojeski E.W., Kline M.D., Haynes D.H. Ultra-long-duration local anesthesia produced by injection of lecithin-coated tetracaine microcrystals. JClin Pharmacol 1994, 34:699-702.
9. Grant G.J., Vermeulen K., Langerman L., Zakowski M., Turndorf H. Prolonged analgesia with liposomal bupivacaine in a mouse model. Reg Anesth 1994, 19:264-269.
10. Mowat J.J., Mok M.J., MacLeod B.A., Madden T.D. Liposomal bupivacaine. Extended duration nerve blockade using large unilamellar vesicles that exhibit a proton gradient. Anesthesiology 1996, 85:635-643.
11. Richard B.M., Ott L.R., Haan D., Brubaker A.N., Cole P.I., Nelson K.G., et al. The safety and tolerability evaluation of DepoFoam bupivacaine (bupivacaine extended-release liposome injection) administered by incision wound infiltration in rabbits and dogs. Expert Opin Investig Drugs 2011, 20:1327-1341.
12. Gorfine S.R., Onel E., Patou G., Krivokapic Z.V. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Dis Colon Rectum 2011, 54:1552-1559.
13. Richard B.M., Newton P., Ott L.R., Haan D., Brubaker A.N., Cole P.I., et al. The safety of EXPAREL (R) (bupivacaine liposome injectable suspension) administered by peripheral nerve block in rabbits and dogs. JDrug Deliv 2012, 2012:962101.
14. Richard B.M., Rickert D.E., Newton P.E., Ott L.R., Haan D., Brubaker A.N., et al. Safety evaluation of EXPAREL (DepoFoam bupivacaine) administered by repeated subcutaneous injection in rabbits and dogs: species comparison. JDrug Deliv 2011, 2011:467429.
15. Golf M., Daniels S.E., Onel E. Aphase 3, randomized, placebo-controlled trial of DepoFoam(R) bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther 2011, 28:776-788.
16. Bramlett K., Onel E., Viscusi E.R., Jones K. Arandomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. Knee 2012, 19:530-536.
17. Minkowitz H.S., Onel E., Patronella C.K., Smoot J.D. Atwo-year observational study assessing the safety of DepoFoam bupivacaine after augmentation mammaplasty. Aesthet Surg J 2012, 32:186-193.
18. Smoot J.D., Bergese S.D., Onel E., Williams H.T., Hedden W. The efficacy and safety of DepoFoam bupivacaine in patients undergoing bilateral, cosmetic, submuscular augmentation mammaplasty: a randomized, double-blind, active-control study. Aesthet Surg J 2012, 32:69-76.
19. Masters D.B., Domb A.J. Liposphere local anesthetic timed-release for perineural site application. Pharm Res 1998, 15:1038-1045.
20. Jia X., Colombo G., Padera R., Langer R., Kohane D.S. Prolongation of sciatic nerve blockade by in situ cross-linked hyaluronic acid. Biomaterials 2004, 25:4797-4804.
21. Kohane D.S., Holmes G.L., Chau Y., Zurakowski D., Langer R., Cha B.H. Effectiveness of muscimol-containing microparticles against pilocarpine-induced focal seizures. Epilepsia 2002, 43:1462-1468.
22. Kohane D.S., Lipp M., Kinney R.C., Anthony D.C., Louis D.N., Lotan N., et al. Biocompatibility of lipid-protein-sugar particles containing bupivacaine in the epineurium. JBiomed Mater Res 2002, 59:450-459.
23. Kohane D.S., Plesnila N., Thomas S.S., Le D., Langer R., Moskowitz M.A. Lipid-sugar particles for intracranial drug delivery: safety and biocompatibility. Brain Res 2002, 946:206-213.
24. Gerner P., Wang C.F., Lee B.S., Suzuki S., Degirolami U., Gandhi A., et al. The relationship between functional sciatic nerve block duration and the rate of release of lidocaine from a controlled-release matrix. Anesth Analg 2010, 111:221-229.
25. Wang C.F., Djalali A.G., Gandhi A., Knaack D., De Girolami U., Strichartz G., et al. An absorbable local anesthetic matrix provides several days of functional sciatic nerve blockade. Anesth Analg 2009, 108:1027-1033.
26. Patenaude M., Hoare T. Injectable, mixed natural-synthetic polymer hydrogels with modular properties. Biomacromolecules 2012, 13:369-378.
27. Lafont N.D., Boogaerts J.G., Legros F.J. Use of liposome-associated bupivacaine for the management of a chronic pain syndrome. Anesth Analg 1994, 79:818.
28. Lafont N.D., Legros F.J., Boogaerts J.G. Use of liposome-associated bupivacaine in a cancer pain syndrome. Anaesthesia 1996, 51:578-579.
29. Boogaerts J.G., Lafont N.D., Declercq A.G., Luo H.C., Gravet E.T., Bianchi J.A., et al. Epidural administration of liposome-associated bupivacaine for the management of postsurgical pain: a first study. JClin Anesth 1994, 6:315-320.
30. Holte K., Werner M.U., Lacouture P.G., Kehlet H. Dexamethasone prolongs local analgesia after subcutaneous infiltration of bupivacaine microcapsules in human volunteers. Anesthesiology 2002, 96:1331-1335.
31. Grant G.J., Barenholz Y., Bolotin E.M., Bansinath M., Turndorf H., Piskoun B., et al. Anovel liposomal bupivacaine formulation to produce ultralong-acting analgesia. Anesthesiology 2004, 101:133-137.
32. Pedersen J.L., Lilleso J., Hammer N.A., Werner M.U., Holte K., Lacouture P.G., et al. Bupivacaine in microcapsules prolongs analgesia after subcutaneous infiltration in humans: a dose-finding study. Anesth Analg 2004, 99:912-918.
33. Kopacz D.J., Lacouture P.G., Wu D., Nandy P., Swanton R., Landau C. The dose response and effects of dexamethasone on bupivacaine microcapsules for intercostal blockade (T9 to T11) in healthy volunteers. Anesth Analg 2003, 96:576-582.
34. Kohane D.S. Biocompatibility and drug delivery systems. Chem Sci 2010, 441-446.
35. Benoit P.W., Belt W.D. Destruction and regeneration of skeletal muscle after treatment with a local anaesthetic, bupivacaine (Marcaine). JAnat 1970, 107:547-556.
36. Benoit P.W., Belt W.D. Some effects of local anesthetic agents on skeletal muscle. Exp Neurol 1972, 34:264-278.
37. Yagiela J.A., Benoit P.W., Buoncristiani R.D., Peters M.P., Fort N.F. Comparison of myotoxic effects of lidocaine with epinephrine in rats and humans. Anesth Analg 1981, 60:471-480.
38. Brun A. Effect of procaine, carbocain and xylocaine on cutaneous muscle in rabbits and mice. Acta Anaesthesiol Scand 1959, 3:59-73.
39. Zink W., Bohl J.R., Hacke N., Sinner B., Martin E., Graf B.M. The long term myotoxic effects of bupivacaine and ropivacaine after continuous peripheral nerve blocks. Anesth Analg 2005, 101:548-554.
40. Colombo G., Padera R., Langer R., Kohane D.S. Prolonged duration local anesthesia with lipid-protein-sugar particles containing bupivacaine and dexamethasone. JBiomed Mater Res A 2005, 75:458-464.
41. Colombo G., Langer R., Kohane D.S. Effect of excipient composition on the biocompatibility of bupivacaine-containing microparticles at the sciatic nerve. JBiomed Mater Res A 2004, 68:651-659.
42. Zink W., Seif C., Bohl J.R., Hacke N., Braun P.M., Sinner B., et al. The acute myotoxic effects of bupivacaine and ropivacaine after continuous peripheral nerve blockades. Anesth Analg 2003, 97:1173-1179.
43. Pere P., Watanabe H., Pitkanen M., Wahlstrom T., Rosenberg P.H. Local myotoxicity of bupivacaine in rabbits after continuous supraclavicular brachial plexus block. Reg Anesth 1993, 18:304-307.
44. Epstein-Barash H., Shichor I., Kwon A.H., Hall S., Lawlor M.W., Langer R., et al. Prolonged duration local anesthesia with minimal toxicity. Proc Natl Acad Sci U S A 2009, 106:7125-7130.
45. Selander D. Neurotoxicity of local anesthetics: animal data. Reg Anesth 1993, 18:461-468.
46. Yamashita A., Matsumoto M., Matsumoto S., Itoh M., Kawai K., Sakabe T. Acomparison of the neurotoxic effects on the spinal cord of tetracaine, lidocaine, bupivacaine, and ropivacaine administered intrathecally in rabbits. Anesth Analg 2003, 97:512-519.
47. Hogan Q., Dotson R., Erickson S., Kettler R., Hogan K. Local anesthetic myotoxicity: a case and review. Anesthesiology 1994, 80:942-947.
48. Rainin E.A., Carlson B.M. Postoperative diplopia and ptosis. A clinical hypothesis based on the myotoxicity of local anesthetics. Arch Ophthalmol 1985, 103:1337-1339.
49. Gomez-Arnau J.I., Yanguela J., Gonzalez A., Andres Y., Garcia del Valle S., Gili P., et al. Anaesthesia-related diplopia after cataract surgery. Br J Anaesth 2003, 90:189-193.
50. Richard B.M., Rickert D.E., Doolittle D., Mize A., Liu J., Lawson C.F. Pharmacokinetic compatibility study of lidocaine with EXPAREL in Yucatan miniature pigs. ISRN Pharm 2011, 2011:582351.
51. Cohen S.M. Extended pain relief trial utilizing infiltration of Exparel((R)), a long-acting multivesicular liposome formulation of bupivacaine: a phase IV health economic trial in adult patients undergoing open colectomy. JPain Res 2012, 5:567-572.
52. Haas E., Onel E., Miller H., Ragupathi M., White P.F. Adouble-blind, randomized, active-controlled study for post-hemorrhoidectomy pain management with liposome bupivacaine, a novel local analgesic formulation. Am Surg 2012, 78:574-581.
53. Ilfeld B.M., Malhotra N., Furnish T.J., Donohue M.C., Madison S.J. Liposomal bupivacaine as a single-injection peripheral nerve block: a dose-response study. Anesth Analg 2013, 117:1248-1256.
54. Rose J.S., Neal J.M., Kopacz D.J. Extended-duration analgesia: update on microspheres and liposomes. Reg Anesth Pain Med 2005, 30:275-285.
55. Thalhammer J.G., Vladimirova M., Bershadsky B., Strichartz G.R. Neurologic evaluation of the rat during sciatic nerve block with lidocaine. Anesthesiology 1995, 82:1013-1025.
56. Kohane D.S., Kuang Y., Lu N.T., Langer R., Strichartz G.R., Berde C.B. Vanilloid receptor agonists potentiate the invivo local anesthetic activity of percutaneously injected site 1 sodium channel blockers. Anesthesiology 1999, 90:524-534.
57. Kohane D.S., Lipp M., Kinney R.C., Lotan N., Langer R. Sciatic nerve blockade with lipid-protein-sugar particles containing bupivacaine. Pharm Res 2000, 17:1243-1249.
58. Kohane D.S., Smith S.E., Louis D.N., Colombo G., Ghoroghchian P., Hunfeld N.G., et al. Prolonged duration local anesthesia from tetrodotoxin-enhanced local anesthetic microspheres. Pain 2003, 104:415-421.
59. Kohane D.S., Yieh J., Lu N.T., Langer R., Strichartz G.R., Berde C.B. Are-examination of tetrodotoxin for prolonged duration local anesthesia. Anesthesiology 1998, 89:119-131.
60. Padera R.F., Tse J.Y., Bellas E., Kohane D.S. Tetrodotoxin for prolonged local anesthesia with minimal myotoxicity. Muscle Nerve 2006, 34:747-753.
61. Anderson J.S.M. Invivo biocompatibility of implantable delivery systems and biomaterials. Eur J Pharm Biopharm 1994, 1994:1-8.
62. McAlvin J.B., Kohane D. Prolonged duration local anesthesia. Advances in delivery science and technology-focal controlled drug delivery 2013, Springer, New York. 1st ed. A.J. Domb, W. Khan (Eds.).
63. Hoare T., Bellas E., Zurakowski D., Kohane D.S. Rheological blends for drug delivery. II. Prolongation of nerve blockade, biocompatibility, and invitro-invivo correlations. JBiomed Mater Res A 2010, 92:586-595.
64. Hoare T., Young S., Lawlor M.W., Kohane D.S. Thermoresponsive nanogels for prolonged duration local anesthesia. Acta Biomater 2012, 8:3596-3605.
65. Sakura S., Bollen A.W., Ciriales R., Drasner K. Local anesthetic neurotoxicity does not result from blockade of voltage-gated sodium channels. Anesth Analg 1995, 81:338-346.
66. Adams H.J., Blair M.R., Takman B.H. The local anesthetic activity of tetrodotoxin alone and in combination with vasoconstrictors and local anesthetics. Anesth Analg 1976, 55:568-573.
67. Adams H.J., Blair M.R., Takman B.H. The local anesthetic activity of saxitoxin alone and with vasoconstrictor and local anesthetic agents. Arch Int Pharmacodyn Ther 1976, 224:275-282.
68. Shichor I., Shomron N., Lawlor M.W., Bae S.A., Zoldan J., Langer R., et al. Toxicogenomic analysis of a sustained release local anesthetic delivery system. Biomaterials 2012, 33:3586-3593.
69. Bergese S.D., Onel E., Morren M., Morganroth J. Bupivacaine extended-release liposome injection exhibits a favorable cardiac safety profile. Reg Anesth Pain Med 2012, 37:145-151.